<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195074</url>
  </required_header>
  <id_info>
    <org_study_id>PL8</org_study_id>
    <nct_id>NCT04195074</nct_id>
  </id_info>
  <brief_title>Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b</brief_title>
  <official_title>Study on Therapeutic Effects and Safety of Three Types of Nucleotide/Nucleoside Analogues in Patients With Chronic Hepatitis b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the clinical efficacy and safety of three types of
      nucleotide/nucleoside analogues in treatment of chronic hepatitis b
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis b (CHB) remains a serious public health problem in China.
      Nucleotide/nucleoside analogues are used for anti-virus treatment in these patients.
      Entecavir, Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide are first line drug in
      China. But there still lacks of data of Tenofovir Alafenamide in treatment of CHB. This study
      is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside
      analogues in treatment of CHB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of renal function decline</measure>
    <time_frame>144 week</time_frame>
    <description>Renal function indicators mainly include blood urea nitrogen, serum creatine and estimated glomerular filtration rate, and the rate of renal function decline would be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of hypercalcemia</measure>
    <time_frame>144 week</time_frame>
    <description>The serum calcium would be detected to know the ratio of patients with hypercalcemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatitis b virus(HBV) DNA undetectable rate</measure>
    <time_frame>0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>Hepatitis b virus DNA would not be detected if it below the upper limit of test value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b e antigen loss rate</measure>
    <time_frame>0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>Hepatitis b e antigen would be tested to know the ratio of patients with negative hepatitis B e antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b s antigen loss rate</measure>
    <time_frame>0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>Hepatitis b s antigen become negative and quantitative analysis below the upper limit of test value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b e antigen seroconversion rate</measure>
    <time_frame>0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>hepatitis b e antibody would be tested to know the ratio of patients with positive hepatitis B e antibody</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>ETV group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.</description>
    <arm_group_label>ETV group</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.</description>
    <arm_group_label>TDF group</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.</description>
    <arm_group_label>TAF group</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive hepatitis b surface antigen or hepatitis b virus DNA &gt; 0.5 year;

          2. Age from 18 to 65 years old;

          3. HBeAg-positive: HBV DNA≥20000IU/ml，HBeAg-negative: HBV DNA≥2000IU/ml；

          4. ALT≥2×ULN；

          5. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

        Exclusion Criteria:

          1. Other active liver diseases;

          2. Hepatocellular carcinoma or other malignancy;

          3. Pregnancy or lactation;

          4. Human immunodeficiency virus infection or congenital immune deficiency diseases;

          5. Severe diabetes, autoimmune diseases;

          6. Other important organ dysfunctions;

          7. Using glucocorticoid;

          8. Patients can not follow-up;

          9. Investigator considering inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Doctor</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 15, 2019</last_update_submitted>
  <last_update_submitted_qc>December 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis b</keyword>
  <keyword>nucleoside</keyword>
  <keyword>nucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

